Pasireotide + Octreotide

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Symptomatic Refractory Resistant Carcinoid Disease

Conditions

Symptomatic Refractory Resistant Carcinoid Disease

Trial Timeline

Apr 1, 2008 → Apr 1, 2012

NCT ID

NCT00690430

About Pasireotide + Octreotide

Pasireotide + Octreotide is a phase 3 stage product being developed by Novartis for Symptomatic Refractory Resistant Carcinoid Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00690430. Target conditions include Symptomatic Refractory Resistant Carcinoid Disease.

What happened to similar drugs?

3 of 16 similar drugs in Symptomatic Refractory Resistant Carcinoid Disease were approved

Approved (3) Terminated (4) Active (9)

✅valsartanNovartisApproved

✅MavacamtenBristol Myers SquibbApproved

✅Droxidopa capsules + Placebo capsulesLundbeckApproved

❌Sodium hyaluronate + placebo injectionDaiichi SankyoPhase 3

🔄ISV-305Sun PharmaceuticalPhase 3

🔄rabeprazole sodium + PlaceboEisaiPhase 3

🔄Esomeprazole + Matching placeboAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00690430	Phase 3	Completed	Apr 1, 2008	Apr 1, 2012	Symptomatic Refractory Resistant Carcinoid Disease
NCT00600886	Phase 3	Completed	Feb 11, 2008	Mar 11, 2016	Acromegaly

Competing Products

20 competing products in Symptomatic Refractory Resistant Carcinoid Disease

See all competitors

Product	Company	Stage	Hype Score
Sodium hyaluronate + placebo injection	Daiichi Sankyo	Phase 3	32
ISV-305	Sun Pharmaceutical	Phase 3	40
rabeprazole sodium + Placebo	Eisai	Phase 3	40
Verinurad + Febuxostat + Dapagliflozin	AstraZeneca	Phase 2	35
RDEA3170 + Febuxostat + Benzbromarone	AstraZeneca	Phase 1/2	32
Esomeprazole + Matching placebo	AstraZeneca	Phase 3	40
DFV890 + Placebo	Novartis	Phase 2	35
Omalizumab + Omalizumab + Placebo	Novartis	Phase 2	35
Tegaserod	Novartis	Phase 2	35
valsartan	Novartis	Approved	43
Atorvastatin - Cholestyramine - Sitosterol	Pfizer	Pre-clinical	26
Epoetin biosimilar	Pfizer	Pre-clinical	26
Apixaban + Standard of care	Pfizer	Phase 3	40
Azithromycin plus chloroquine	Pfizer	Phase 3	32
Mavacamten	Bristol Myers Squibb	Approved	50
Aficamten + Placebo	Sanofi	Phase 3	44
Vandetanib 300 mg	Sanofi	Pre-clinical	26
REGN7508 + Acetylsalicylic Acid (ASA) + Placebo	Regeneron Pharmaceuticals	Phase 3	47
Rivaroxaban + Placebo	Bayer	Phase 3	37
Droxidopa capsules + Placebo capsules	Lundbeck	Approved	40